Year: 2017
Type: article
Study design: Observational Study
Abstract: A cute graft-versus-host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances have resulted in improved outcome specifically among those diagnosed with acute graft-versus-host disease. We examined outcome following diagnosis of grade II-IV acute graft-versus-host disease according to time period, and explored effects according to original graft-versus-host disease prophylaxis regimen and maximum overall grade of acute graft-versus-host disease. Between 1999 and 2012, 2,905 patients with acute myeloid leukemia (56%), acute lymphoblastic leukemia (30%) or myelodysplastic syndromes (14%) received a sibling (24%) or unrelated donor (76%) blood (66%) or marrow (34%) transplant and developed grade II-IV acute graft-versus-host disease (n=497 for 1999–2001, n=962 for 2002–2005, n=1,446 for 2006–2010). The median (range) follow-up was 144 (4–174), 97 (4–147) and 60 (8–99) months for 1999–2001, 2002–2005, and 2006–2010, respectively. Among the cohort with grade II-IV acute graft-versus-host disease, there was a decrease in the proportion of grade III-IV disease over time with 56%, 47%, and 37% for 1999–2001, 2002–2005, and 2006–2012, respectively (P
Source: Haematologica
Authors: Hanna J. Khoury, Tao Wang, Michael T. Hemmer, Daniel Couriel, Amin Alousi, Corey Cutler, Mahmoud Aljurf, Joseph H. Antin, Mouhab Ayas, Minoo Battiwalla, Jean-Yves Cahn, Mitchell Cairo, Yi-Bin Chen, Robert Peter Gale, Shahrukh Hashmi, Robert J. Hayashi, Madan Jagasia, Mark Juckett, Rammurti T. Kamble, Mohamed Kharfan-Dabaja, Mark Litzow, Navneet Majhail, Alan Miller, Taiga Nishihori, Muna Qayed, Helene Schoemans, Harry C. Schouten, Gerard Socie, Jan Storek, Leo Verdonck, Ravi Vij, William A. Wood, Lolie Yu, Rodrigo Martino, Matthew Carabasi, Christopher Dandoy, Usama Gergis, Peiman Hematti, Melham Solh, Kareem Jamani, Leslie Lehmann, Bipin Savani, Kirk R. Schultz, Baldeep M. Wirk, Stephen Spellman, Mukta Arora, Joseph Pidala
Institutions: Emory University, Winship Cancer Institute, Medical College of Wisconsin, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, King Faisal Specialist Hospital & Research Centre, National Institutes of Health, National Heart, Lung, and Blood Institute, Centre Hospitalier Universitaire de Grenoble, New York Medical College, Massachusetts General Hospital, Imperial College London, Mayo Clinic, Washington University in St. Louis, Vanderbilt University Medical Center, University of Wisconsin–Madison, UW Health University Hospital, Baylor College of Medicine, Moffitt Cancer Center, Cleveland Clinic, Universitair Ziekenhuis Leuven, Maastricht University Medical Centre, Hôpital Saint-Louis, University of Calgary, Isala, University of North Carolina at Chapel Hill, Louisiana State University, University Medical Center New Orleans, Center for Cancer and Blood Disorders, Children's Hospital of New Orleans, Louisiana State University Health Sciences Center New Orleans, Hospital de Sant Pau, Thomas Jefferson University Hospital, Cincinnati Children's Hospital Medical Center, NewYork–Presbyterian Hospital, Weill Cornell Medical Center, Northside Hospital, Boston Children's Hospital, University of British Columbia, BC Children's Hospital, Seattle Cancer Care Alliance, National Marrow Donor Program, University of Minnesota Medical Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
Funders: U.S. Department of Defense, U.S. Department of Health and Human Services, Amgen, Bristol-Myers Squibb, Pfizer, Astellas Pharma US, AstraZeneca, Sanofi, WellPoint, Gilead Sciences, Patient-Centered Outcomes Research Institute, Alexion Pharmaceuticals, Spectrum Pharmaceuticals, Celgene, HistoGenetics, University of Minnesota, Novartis Pharmaceuticals Corporation, Medical College of Wisconsin, Jazz Pharmaceuticals, Sunesis, bluebird bio, Telomere Diagnostics, Janssen Scientific Affairs, Incyte, Otsuka America, Astellas Pharma, Otsuka Pharmaceutical, Swedish Orphan Biovitrum, Medac, National Institutes of Health, Health Resources and Services Administration, Genentech, Onyx Pharmaceuticals, U.S. Navy, Takeda Oncology, National Heart, Lung, and Blood Institute, Office of Naval Research, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Center for Advancing Translational Sciences
Awards: G1384772222, G1626132361, G1769371581, G226656, G2814340220, G3816434386, G3847019374, G4298420724, G4373273904, G4930744573, G5214925129, G5706912026, G6771248800, G6850693576, Blood & Marrow Transplant Clinical Trials Network Data Coordinating Center, G8649229721, G8876996369, Institutional Career Development Core, A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research, Georgia Clinical & Translational Science Alliance (Georgia CTSA)
OpenAlex ID: W2595098826